Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Single-arm, Open-label and Fixed-sequence Study to Evaluate the Effect of Omeprazole on Pharmacokinetics of Famitinib Malate in Healthy Adult Subjects

Next Previous
Trial Profile

A Single-centre, Single-arm, Open-label and Fixed-sequence Study to Evaluate the Effect of Omeprazole on Pharmacokinetics of Famitinib Malate in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Famitinib (Primary) ; Omeprazole (Primary)
  • Indications Biliary cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Thyroid cancer; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 22 May 2023 Status changed from active, no longer recruiting to completed.
  • 10 Sep 2022 Results assessing the potential gastric pH-dependent drug-drug interaction (DDI), safety and tolerability of famitinib co-administered with omeprazole in healthy subjects, published in the Investigational New Drugs.
  • 16 Nov 2021 Planned End Date changed from 13 Oct 2021 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top